Deletion mutant of a set of hepatitis B HBx gene and application thereof

Abstract

The invention provides a deletion mutant of hepatitis B HBX gene, wherein SEQ ID NO. 1 is a mutant lack of 264 bases in 1577-1840 HBV nucleic acid position; SEQ ID NO. 2 is a HBX gene mutant lack of 19 bases in 382-400 nucleic acid position; SEQ ID NO. 3 is a HBX gene mutant lack of 15 bases in 431-445 nucleic acid position. The deletion mutant is provided with apparent oncogenic effect, which can be used to the gene detection of hepatitis B etiological agent carrier and hepatic carcinoma.

Description

technical field [0001] The invention belongs to the field of biomedicine, and specifically relates to a group of deletion mutants of hepatitis B HBx gene and its application in clinical diagnosis, treatment and prevention. Background technique [0002] Primary hepatocellular carcinoma (HCC) is one of the most common malignant tumors in Southeast Asia and China. A large number of epidemiological surveys have shown that long-term chronic hepatitis B virus infection is the main cause of HCC. The risk of HCC in people infected with HBV It is more than 100 times that of uninfected patients, and HCC patients have a tendency to cluster HBV infection in their families, suggesting that HBV infection is closely related to the occurrence of HCC. [0003] HBV is a partially double-stranded DNA virus with a genome of 3.2kb, including S, C, P, and X four open reading frames, among which the X gene is the smallest open reading frame and the region with the most obvious functional overlap. ...

AI Technical Summary

Problems solved by technology

So far, there have been no reports of HBx gene deletion mutations directly causing HCC, and no reports of HBx gene deletion mutants being used for clinical diagnosis and treatment.